A Randomized, Placebo Controlled Study to Determine the Effect of Two Dose Schedules of R1507 or Placebo, Both in Combination With Erlotinib (Tarceva®), on Progression-free Survival in Patients With Advanced Non-small Cell Lung Cancer With Disease Progression After First or Second Line Chemotherapy

Inclusion Criteria:

- male or female patients >=18 years with histologically documented inoperable, locally
advanced or metastatic (stage IIIB or IV) NSCLC;

- patients must have failed at least one but no more than two standard chemotherapy
regimens;

- measurable disease according to the RECIST criteria;

- ECOG performance status;

- life expectancy >12 weeks.

Exclusion Criteria:

- patients with active CNS lesions;

- prior treatment with agents acting via IGF-1R inhibition or EGFR targeting;

- administration with high doses of systemic corticosteroids;

- radiotherapy in the 4 weeks prior to study start;

- surgery or significant traumatic injury with in the last 2 weeks prior to study
start.